T. Rowe Price Associates’s Tenaya Therapeutics TNYA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$22K Hold
31,453
﹤0.01% 3116
2025
Q4
$23K Hold
31,453
﹤0.01% 3076
2025
Q3
$51K Sell
31,453
-36,129
-53% -$36.4K ﹤0.01% 3011
2025
Q2
$42K Sell
67,582
-21,988
-25% -$11.2K ﹤0.01% 3019
2025
Q1
$52K Sell
89,570
-46,664
-34% -$46K ﹤0.01% 2923
2024
Q4
$196K Sell
136,234
-2,892,201
-96% -$6.48M ﹤0.01% 2691
2024
Q3
$5.84M Sell
3,028,435
-485,289
-14% -$1.37M ﹤0.01% 1252
2024
Q2
$10.9M Buy
3,513,724
+167,202
+5% +$690K ﹤0.01% 1097
2024
Q1
$17.5M Sell
3,346,522
-1,198,021
-26% -$5.73M ﹤0.01% 1007
2023
Q4
$14.7M Buy
4,544,543
+69,377
+2% +$150K ﹤0.01% 1019
2023
Q3
$11.4M Buy
4,475,166
+5,525
+0.1% +$23.1K ﹤0.01% 1053
2023
Q2
$26.2M Buy
4,469,641
+82,858
+2% +$482K ﹤0.01% 863
2023
Q1
$12.5M Sell
4,386,783
-85,419
-2% -$240K ﹤0.01% 1018
2022
Q4
$8.99M Buy
4,472,202
+2,357,950
+112% +$5.76M ﹤0.01% 1071
2022
Q3
$6.13M Sell
2,114,252
-1,252,528
-37% -$5.85M ﹤0.01% 1164
2022
Q2
$19M Buy
3,366,780
+335,378
+11% +$2.71M ﹤0.01% 1182
2022
Q1
$35.7M Buy
3,031,402
+37,899
+1% +$459K ﹤0.01% 1076
2021
Q4
$55.6M Buy
2,993,503
+220,394
+8% +$4.8M 0.01% 962
2021
Q3
$56M Buy
+2,773,109
New +$59.6M 0.01% 967

Other funds holding TNYA

T. Rowe Price Associates's TNYA Position: Q1 2026 in Review

T. Rowe Price Associates held its Tenaya Therapeutics (TNYA) position steady in Q1 2026 at 31,453 shares worth $22K. The position accounts for ﹤0.01% of the portfolio, ranked #3116.

T. Rowe Price Associates first reported a position in TNYA in Q3 2021 and has held it in 19 quarters since. The position peaked at $56M in Q3 2021. 103 funds tracked by Wall St. Rank hold TNYA as of Q1 2026.

  • T. Rowe Price Associates held 31,453 shares of Tenaya Therapeutics worth $22K as of Q1 2026.
  • T. Rowe Price Associates left its Tenaya Therapeutics share count unchanged in Q1 2026.
  • Tenaya Therapeutics made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #3116 holding.
  • T. Rowe Price Associates first reported a position in Tenaya Therapeutics in Q3 2021 and has held it in 19 quarters since.
  • T. Rowe Price Associates's Tenaya Therapeutics position peaked at $56M in Q3 2021.
  • 103 funds tracked by Wall St. Rank held Tenaya Therapeutics as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.